Antidepressants modulate intracellular amyloid peptide species in N2a neuroblastoma cells

Journal of Alzheimer's Disease

Volumn 24, Issue 2, 2011, Pages 221-234

  Aboukhatwa, Marwa ^a   Luo, Yuan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Alzheimer's disease; amyloid beta toxicity; antidepressant drugs; cell model

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MONOMER; OLIGOMER; PAROXETINE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE OVEREXPRESSION; INTRACELLULAR SPACE; MOLECULAR MECHANICS; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; WESTERN BLOTTING;

EID: 79955640894     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-101113     Document Type: Article

References (97)

1. Walsh DM, Selkoe DJ (2007) A beta oligomers-a decade of discovery. J Neurochem 101, 1172-1184.
2. Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283, 29639-29643.
3. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A (2009) Beta-amyloid monomers are neuroprotective. J Neurosci 29, 10582-10587.
4. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37, 925-937. (Pubitemid 36398299)
5. Tyeryar KR, Vongtau HO, Undieh AS (2008) Diverse anti-depressants increase CDP-diacylglycerol production and phosphatidylinositide resynthesis in depression-relevant regions of the rat brain. BMC Neurosci 9, 12.
6. Tyeryar KR, Undie AS (2007) Tandem regulation of phos-phoinositide signaling and acute behavioral effects induced by antidepressant agents in rats. Psychopharmacology (Berl) 193, 271-282. (Pubitemid 47025029)
7. Stokes CE, Hawthorne JN (1987) Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J Neurochem 48, 1018-1021. (Pubitemid 18001319)
8. Landman N, Jeong SY, Shin SY, Voronov SV, Serban G, Kang MS, Park MK, Di Paolo G, Chung S, Kim TW (2006) Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc Natl Acad Sci USA 103, 19524-19529. (Pubitemid 46026064)
9. Berman DE, Dall'Armi C, Voronov SV, McIntire LB, Zhang H, Moore AZ, Staniszewski A, Arancio O, Kim TW, Di Paolo G (2008) Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. NatNeu-rosci 11, 547-554. (Pubitemid 351595195)
10. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, Nemeroff CB, Bremner JD, Carney RM, Coyne JC, Delong MR, Frasure-Smith N, Glassman AH, Gold PW, Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kaufmann PG, Keefe FJ, Ketter T, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH, Musselman D, O'Connor C, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J, Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits P Jr, Valvo WJ (2005) Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58, 175-189. (Pubitemid 41112265)
11. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63, 530-538.
12. Bassuk SS, Berkman LF, Wypij D (1998) Depressive symp-tomatology and incident cognitive decline in an elderly community sample. Arch Gen Psychiatry 55, 1073-1081. (Pubitemid 28558278)
13. Lyketsos CG, Steele C, Baker L, Galik E, Kopunek S, Steinberg M, Warren A (1997) Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsy-chiatry ClinNeurosci 9, 556-561. (Pubitemid 28029749)
14. Lee HB, Lyketsos CG (2003) Depression in Alzheimer's dis-ease: heterogeneity and related issues. Biol Psychiatry 54, 353-362. (Pubitemid 37270616)
15. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L (2003) Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 60, 753-759. (Pubitemid 36569895)
16. Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T (2003) A collaborative study of the emer-gence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry 160, 857-866. (Pubitemid 41079569)
17. Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, Folstein MF, Price DL (1988) The neu-ropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 24, 233-242.
18. Zubenko GS, Moossy J (1988) Major depression in primary dementia. Clinical and neuropathologic correlates. ArchNeu-rol 45, 1182-1186.
19. Sapolsky RM (2000) Glucocorticoids and hippocampal atro-phy in neuropsychiatric disorders. Arch Gen Psychiatry 57, 925-935.
20. Lyketsos CG, Olin J (2002) Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 52, 243-252. (Pubitemid 35232091)
21. Thompson S, Herrmann N, Rapoport MJ, Lanctot KL (2007) Efficacy and safety of antidepressants for treatment of depres-sion in Alzheimer's disease: a meta analysis. Canad J Psychiatry 52, 248-255. (Pubitemid 46743472)
22. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, Refsum HE, Ofsti E, Eriksson S, Syversen S (1992) A controlled multicenter clin-ical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psy-chiatr Scand 86, 138-145.
23. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, Brandt J, Rabins PV (2000) Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. AmJPsychiatry 157, 1686-1689.
24. Francis PT, Ramirez MJ, Lai MK (2010) Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neu-ropharmacology 59, 221-229.
25. Decker MW, McGaugh JL (1991) The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7, 151-168.
26. Rossor M, Iversen LL (1986) Non-cholinergic neurotrans-mitter abnormalities in Alzheimer's disease. Brit Med Bull 42, 70-74. (Pubitemid 16185783)
27. Lai MK, Tsang SW, Francis PT, Keene J, Hope T, Esiri MM, Spence I, Chen CP (2002) Postmortem serotoninergic corre-lates of cognitive decline in Alzheimer's disease. Neuroreport 13, 1175-1178. (Pubitemid 34722048)
28. Riekkinen M, Tolonen R, Riekkinen P Jr (1994) Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behavior. Brain Res 649, 174-180.
29. Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ (2006) Serotonin and human cognitive performance. Curr PharmDes 12, 2473-2486. (Pubitemid 44026030)
30. Mowla A, Mosavinasab M, Haghshenas H, Haghighi AB (2007) Does serotonin augmentation have any effect on cog-nition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psy-chopharmacol 27, 484-487. (Pubitemid 47415047)
31. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, Staib LH, Charney DS, Bremner JD (2004) Hippocampal volume, memory, and cortisol sta-tus in major depressive disorder: effects of treatment. Biol Psychiatry 56, 101-112. (Pubitemid 38844785)
32. Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T (2004) A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpa-tients treated with donepezil. Int J Geriatr Psychiatry 19, 9-18. (Pubitemid 38180687)
33. Aboukhatwa M, Dosanjh L, Luo Y (2010) Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Mol Neurodegener 5, 10.
34. Verret L, Jankowsky JL, Xu GM, Borchelt DR, Rampon C (2007) Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hip-pocampal neurogenesis. J Neurosci 27, 6771-6780. (Pubitemid 46983445)
35. Chevallier NL, Soriano S, Kang DE, Masliah E, Hu G, Koo EH (2005) Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am J Pathol 167, 151-159. (Pubitemid 40884778)
36. Dong H, Goico B, Martin M, Csernansky CA, Bertchume A, Csernansky JG (2004) Modulation of hippocampal cell pro-liferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 127, 601-609. (Pubitemid 38993164)
37. Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ (2006) Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol 495, 70-83. (Pubitemid 43238052)
38. Haughey NJ, Liu D, Nath A, Borchard AC, Mattson MP (2002) Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromol Med 1, 125-135. (Pubitemid 37012521)
39. Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP (2002) Disruption of neurogenesis by amyloid beta-peptide, and perturbeneural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem 83, 1509-1524. (Pubitemid 35477489)
40. Wen PH, Shao X, Shao Z, Hof PR, Wisniewski T, Kelley K, Friedrich VL Jr, Ho L, Pasinetti GM, Shioi J, Robakis NK, Elder GA (2002) Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis 10, 8-19. (Pubitemid 34757077)
41. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20, 9104-9110. (Pubitemid 32042912)
42. Warner-Schmidt JL, Duman RS (2006) Hippocampal neu-rogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16, 239-249.
43. Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, Zhang YJ, Nestler EJ, Duman RS (2002) Regulation of neuro-genesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. JNeurosci 22, 3673-3682. (Pubitemid 37465772)
44. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120, 701-713. (Pubitemid 40343081)
45. Mattson MP, Maudsley S, Martin B (2004) BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurode-generative disorders. Trends Neurosci 27, 589-594. (Pubitemid 39221394)
46. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, Mason J, Morgan DG, Morgan TE, Finch CE (2005) Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging 26, 995-1000. (Pubitemid 40312661)
47. Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, Brown M, Martin B, Iyun T, Maudsley S, Clark RF, Mattson MP (2007) Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol 205, 166-176. (Pubitemid 46617502)
48. Russo-Neustadt A (2003) Brain-derived neurotrophic factor, behavior, and new directions for the treatment of mental dis-orders. Sem Clin Neuropsychiatry 8, 109-118. (Pubitemid 36828242)
49. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR (2002) An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277, 45518-45528. (Pubitemid 36159162)
50. Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT (2003) Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci 20, 267-275. (Pubitemid 38146981)
51. Tucker S, Ahl M, Bush A, Westaway D, Huang X, Rogers JT (2005) Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5' untranslated region. CurrAlz Res 2, 249-254. (Pubitemid 40862888)
52. Tucker S, Ahl M, Cho HH, Bandyopadhyay S, Cuny GD, Bush AI, Goldstein LE, Westaway D, Huang X, Rogers JT (2006) RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxe-tine, erythromycin, and N-acetyl cysteine. Curr Alz Res 3, 221-227. (Pubitemid 43988135)
53. Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS (1996) Metabolism of the "Swedish" amyloid precursor protein variant in neuro2 a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. JBiol Chem 271, 9390-9397.
54. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555. (Pubitemid 40269768)
55. Gandy S (2005) The role of cerebral amyloid beta accumu-lation in common forms of Alzheimer disease. J Clin Invest 115, 1121-1129. (Pubitemid 40629026)
56. Gross RW, Jenkins CM, Yang J, Mancuso DJ, Han X (2005) Functional lipidomics: the roles of specialized lipids and lipid-protein interactions in modulating neuronal function. Prostaglandins Other Lipid Mediat 77, 52-64. (Pubitemid 41133415)
57. Hofgaard JP, Banach K, Mollerup S, Jorgensen HK, Olesen SP, Holstein-Rathlou NH, Nielsen MS (2008) Phos-phatidylinositol-bisphosphate regulates intercellular coupling in cardiac myocytes. Pflugers Arch 457, 303-313.
58. Nakanishi S, Catt KJ, Balla T (1995) A wortmannin-sensitive phosphatidylinositol 4-kinase that regulates hormone-sensitive pools of inositolphospholipids. Proc Natl Acad Sci US A 92, 5317-5321.
59. Peselow ED, Corwin J, Fieve RR, Rotrosen J, Cooper TB (1991) Disappearance of memory deficits in outpatient depressives responding to imipramine. J Affect Disord 21, 173-183.
60. Song L, Che W, Min-Wei W, Murakami Y, Matsumoto K (2006) Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol Biochem Behav 83, 186-193.
61. Wille SM, Cooreman SG, Neels HM, Lambert WE (2008) Relevant issues in the monitoring and the toxicology of anti-depressants. Crit Rev Clin Lab Sci 45, 25-89. (Pubitemid 351299653)
62. Winek CL, Wahba WW, Winek CL, Jr., Balzer TW (2001) Drug and chemical blood-level data 2001. Forensic Sci Int 122, 107-123. (Pubitemid 32979233)
63. DeVane CL, Simpkins JW, Stout SA (1984) Cerebral and blood pharmacokinetics of imipramine and its active meta-bolites in the pregnant rat. Psychopharmacology (Berl) 84, 225-230. (Pubitemid 14006577)
64. Kolla N, Wei Z, Richardson JS, Li XM (2005) Amitriptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide. JPsychiatry Neurosci 30, 196-201. (Pubitemid 40942458)
65. Hwang J, Zheng LT, Ock J, Lee MG, Kim SH, Lee HW, Lee WH, Park HC, Suk K (2008) Inhibition of glial inflamma-tory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 55, 826-834.
66. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27, 570-575. (Pubitemid 43290525)
67. Arispe N, Pollard HB, Rojas E (1994) beta-Amyloid Ca(2+)-channel hypothesis for neuronal death in Alzheimer disease. Mol Cell Biochem 140, 119-125.
68. Arispe N, Rojas E, Pollard HB (1993) Alzheimer disease amyloid beta protein forms calcium channels in bilayer mem-branes: blockade by tromethamine and aluminum. Proc Natl AcadSci US A 90, 567-571. (Pubitemid 23028904)
69. Kagan BL, Azimov R, Azimova R (2004) Amyloid peptide channels. J Membr Biol 202, 1-10. (Pubitemid 40298660)
70. Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, Dobson CM, Stefani M (2004) Prefibrillar amyloid protein aggre-gates share common features of cytotoxicity. J Biol Chem 279, 31374-31382. (Pubitemid 39037804)
71. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG (2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amy-loid oligomers in protein misfolding diseases. J Biol Chem 279, 46363-46366. (Pubitemid 39518276)
72. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280, 17294-17300. (Pubitemid 41389198)
73. Deshpande A, Mina E, Glabe C, Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by dis-tinct mechanisms in human cortical neurons. J Neurosci 26, 6011-6018. (Pubitemid 44318367)
74. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci USA 100, 6370-6375. (Pubitemid 36666588)
75. Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS (1995) The toxicity in vitro of beta-amyloid protein. Biochem J311 (Pt 1), 1-16.
76. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc NatlAcadSci USA91, 12243-12247. (Pubitemid 24368641)
77. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermedi-ates of amyloid beta-protein induce acute electrophysiologi-cal changes and progressive neurotoxicity in cortical neurons. J Neurosci 19, 8876-8884. (Pubitemid 30226709)
78. Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, Suzuki H, Araki W, Inoue H, Shirotani K, Takahashi K, Gallyas F, Tabira T (1999) Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. NatMed 5, 560-564. (Pubitemid 29220216)
79. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochem-istry 39, 10831-10839.
80. Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y (1999) Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. AmJ Pathol 155, 23-28. (Pubitemid 29318698)
81. Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, Ihara Y (1999) Appearance of sodium dode-cyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol 154, 271-279. (Pubitemid 29031634)
82. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocam-pal long-term potentiation in vivo. Nature 416, 535-539. (Pubitemid 34288854)
83. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572, 477-492.
84. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11, 556-561. (Pubitemid 40685979)
85. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal Abeta42 accumulation in humanbrain. Am J Pathol 156, 15-20.
86. Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59, 358-365.
87. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006) Opposing activities protect against age-onset proteo-toxicity. Science 313, 1604-1610. (Pubitemid 44414028)
88. Cohen E, Dillin A (2008) The insulin paradox: aging, pro-teotoxicity and neurodegeneration. Nat Rev Neurosci 9, 759-767.
89. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-260.
90. Zhao WQ, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2009) Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem 284, 18742-18753.
91. Mukhopadhyay A, OhSW, TissenbaumHA (2006) Worming pathways to and from DAF-16/FOXO. Exp Gerontol 41, 928-934. (Pubitemid 44822652)
92. Murphy CT (2006) The search for DAF-16/FOXO transcriptional targets: approaches and discoveries. Exp Gerontol 41, 910-921. (Pubitemid 44821691)
93. Murakami H, Murakami S (2007) Serotonin receptors antago-nistically modulate Caenorhabditis elegans longevity. Aging Cell 6, 483-488. (Pubitemid 47087053)
94. Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, Perault-Pochat MC, Lafay-Chebassier C (2010) Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 332, 505-514.
95. Counts SE, Mufson EJ (2010) Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J Neurochem 113, 649-660.
96. Pakaski M, Bjelik A, Hugyecz M, Kasa P, Janka Z, Kalman J (2005) Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int 47, 190-195. (Pubitemid 40848681)
97. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimerbeta/A4 amyloidproteinprecursor. ProcNatlAcad Sci USA 89, 10075-10078.